Frequencies of MDM2 SNP309 in controls and cancer patients
| Cohorts and subgroups | No. of individuals | No. of individuals according to SNP309 genotype (%) | Pearson χ2* | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wild type | Heterozygote | Homozygote | p value | |||||||
| *Subgroup versus subgroup; †group versus healthy controls. EO, early onset. | ||||||||||
| Healthy controls | 185 | 56 (31) | 98 (53) | 31 (16) | ||||||
| EO leiomyosarcomas | 68 | 21 (31) | 36 (53) | 11 (16) | 0.99† | |||||
| Age <41 years | 33 | 9 (27) | 20 (61) | 4 (12) | 0.44 | |||||
| Age >41 years | 35 | 12 (34) | 16 (46) | 7 (20) | ||||||
| Familial cancer | 38 | 11 (29) | 19 (50) | 8 (21) | 0.47 | |||||
| No familial cancer | 30 | 10 (33) | 17 (57) | 3 (10) | ||||||
| Local tumour | 49 | 14 (29) | 28 (57) | 7 (14) | 0.21 | |||||
| Diffused tumour | 5 | 2 (40) | 1 (20) | 2 (40) | ||||||
| CRC | 969 | 334 (34) | 465 (48) | 170 (18) | 0.44† | |||||
| Microsatellite stable | 849 | 294 (34.5) | 397 (47) | 158 (18.5) | 0.04 | |||||
| Microsatellite unstable | 120 | 40 (33) | 68 (57) | 12 (10) | ||||||
| Female | 481 | 147 (31) | 239 (50) | 95 (20) | 0.02 | |||||
| Male | 488 | 187 (38) | 226 (46) | 75 (15) | ||||||
| Multiple cancer | 124 | 42 (34) | 52 (42) | 30 (24) | 0.10 | |||||
| A single CRC, no other | 845 | 292 (34.5) | 413 (49) | 140 (16.5) | ||||||
| Malignancies | ||||||||||
| Dukes A-B | 572 | 185 (32) | 282 (49) | 105 (18) | 0.24 | |||||
| Dukes C-D | 391 | 147 (38) | 180 (46) | 64 (16) | ||||||
| Grade 1 | 192 | 69 (36) | 97 (50.5) | 26 (13.5) | 0.40 | |||||
| Grade 2 | 677 | 225 (33) | 326 (48) | 126 (19) | ||||||
| Grade 3–4 | 80 | 32 (40) | 34 (42.5) | 14 (17.5) | ||||||
| Familial CRC | 835 | 282 (34) | 401 (48) | 152 (18) | 0.31 | |||||
| No familial CRC | 134 | 52 (39) | 64 (48) | 18 (13) | ||||||
| Familial cancer | 436 | 146 (33) | 209 (48) | 81 (19) | 0.70 | |||||
| No famililal cancer | 533 | 188 (35) | 256 (48) | 89 (17) | ||||||
| SCCHN | 157 | 58 (37) | 75 (48) | 24 (15) | 0.47† | |||||
| Age ⩽61 years | 84 | 32 (38) | 42 (50) | 10 (12) | 0.45 | |||||
| Age >61 years | 73 | 26 (36) | 33 (45) | 14 (19) | ||||||
| Recurrent SCCHN | 122 | 44 (36) | 60 (49) | 18 (15) | 0.88 | |||||
| no recurrence | 32 | 13 (41) | 15 (47) | 4 (12) | ||||||
| T1 tumours | 68 | 28 (41) | 31 (46) | 9 (13) | 0.6 | |||||
| T⩾2 tumours | 89 | 30 (34) | 44 (49) | 15 (17) | ||||||
| N0 tumours | 108 | 43 (40) | 46 (42.5) | 19 (17.5) | 0.14 | |||||
| N+ tumours | 49 | 15 (31) | 29 (49) | 5 (10) | ||||||